{
  "meta": {
    "timestamp": "2025-01-06T10:47:37.674886",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Embecta Corp.",
      "symbol": "EMBC",
      "analysis": {
        "historical": {
          "risk_score": 65,
          "key_risks": [
            "Regulatory and compliance risks due to dependence on FDA and EMA approvals",
            "Supply chain vulnerabilities impacting margins",
            "Intense competitive pressures in the diabetes care market",
            "Pricing and reimbursement challenges in emerging markets",
            "Transitional risks from recent spin-off from Becton, Dickinson and Company"
          ],
          "controversies": [
            "Halted insulin patch pump program signaling potential strategic pivots",
            "Reliance on former BD executives for board roles raising independence concerns"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Potential impact on delivering affordable and accessible diabetes care solutions in underserved markets"
          ],
          "governance_issues": [
            "Questions about board independence and oversight due to reliance on former BD executives"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Advancing every day together 2024 - embecta Corp.",
              "snippet": "of embecta's management, or persons who held embecta management responsibilities within the preceding three years, may be members of the Board at any given time. The size of the Board, its operational principles, compensation practices and ethical codes, among other Board topics, are covered in our Corporate Governance Principles.1 >100",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. regulatory compliance issues",
              "retrieved_at": "2025-01-06T17:47:07.392178+00:00",
              "published_date": null,
              "source_hash": "d9f3cce70cd5c9c594ab54c2b992b659"
            },
            {
              "url": "",
              "title": "EMBECTA CORP. CHARTER OF THE AUDIT COMMITTEE Purpose",
              "snippet": "EMBECTA CORP. CHARTER OF THE AUDIT COMMITTEE Effective March 20, 2022 \u2212 any communications between the audit team and the audit firm's national office regarding auditing or accounting issues presented by the engagement; \u2212 any management or internal control letter issued, or proposed to be issued, by the",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. regulatory compliance issues",
              "retrieved_at": "2025-01-06T17:47:07.392241+00:00",
              "published_date": null,
              "source_hash": "5843df3e373ebb6b11fa9058cdbd60ab"
            },
            {
              "url": "",
              "title": "Embecta Corp. Code of Conduct",
              "snippet": "This Code of Conduct (the \"Code\") sets the foundation for how we conduct business at Embecta Corp. (\"embecta\") consistent with our values. To the extent our Code requires a higher standard than required by applicable laws, rules or regulations, embecta adheres to these higher standards. Our Code provides",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. regulatory compliance issues",
              "retrieved_at": "2025-01-06T17:47:07.392258+00:00",
              "published_date": null,
              "source_hash": "95a34d158e2a6b012b8cf7a840064996"
            },
            {
              "url": "",
              "title": "embecta - Regulatory Affairs and Compliance | The Org",
              "snippet": "The Regulatory Affairs and Compliance team at embecta is responsible for ensuring that all diabetes care products meet regulatory standards and compliance requirements throughout their lifecycle. They engage with health authorities, manage submissions for product approvals, and oversee adherence to regulatory guidelines, fostering innovation ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. regulatory compliance issues",
              "retrieved_at": "2025-01-06T17:47:07.392267+00:00",
              "published_date": null,
              "source_hash": "345297024a0323bf2ed0f508a0c43fca"
            },
            {
              "url": "",
              "title": "SEC.gov | HOME",
              "snippet": "Embecta Corp. 300 Kimball Drive, Ste 300 Parsippany, New Jersey 07054 www.embecta.com. December 30, 2022. Dear fellow stockholders, ... safety or regulatory registration or compliance issues. The TQR Committee also reviews product quality, safety or regulatory registration or compliance risks identified in connection with acquisitions and the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. regulatory compliance issues",
              "retrieved_at": "2025-01-06T17:47:07.392276+00:00",
              "published_date": null,
              "source_hash": "cb9a98ffbd6d48361ed5d7e35946d5f2"
            },
            {
              "url": "",
              "title": "Embecta Corp. ESG Risk Rating - Sustainalytics",
              "snippet": "Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. regulatory compliance issues",
              "retrieved_at": "2025-01-06T17:47:07.392285+00:00",
              "published_date": null,
              "source_hash": "04a77c853603724b79cbfcdf20bcd0e4"
            },
            {
              "url": "",
              "title": "EMBC / Embecta Corp. - SEC Filings, Annual Report, Proxy Statement - Fintel",
              "snippet": "2024-05-28: EX-1.01: Conflict Minerals Report for the calendar year ended December 31, 2023. Exhibit 1.01 Conflict Minerals Report Embecta Corp. has included this Conflict Minerals Report as an exhibit to its Form SD for 2023, as contemplated by Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and Form SD (collectively, the \"Conflict Minerals Rule\").",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. regulatory compliance issues",
              "retrieved_at": "2025-01-06T17:47:07.392293+00:00",
              "published_date": null,
              "source_hash": "f4e52fbbd40e76a5726881ee89199891"
            },
            {
              "url": "",
              "title": "Embecta Corp. -- Moody's assigns Ba3 rating to Embecta Corp. proposed ...",
              "snippet": "Rating Action: Moody's assigns Ba3 rating to Embecta Corp. proposed senior secured notesGlobal Credit Research - 24 Jan 2022New York, January 24, 2022 -- Moody's Investors Service (\"Moody's ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. regulatory compliance issues",
              "retrieved_at": "2025-01-06T17:47:07.392302+00:00",
              "published_date": null,
              "source_hash": "97a56cf98a77e600e8a1ca48824765f7"
            },
            {
              "url": "",
              "title": "Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year ...",
              "snippet": "PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (\"embecta\" or the \"Company\") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Embecta Corp. Embecta Corp. pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:47:16.436647+00:00",
              "published_date": null,
              "source_hash": "d322ab7a38bc87daee837fb369fdbd30"
            },
            {
              "url": "",
              "title": "Embecta shutters newly cleared insulin patch pump program amid layoffs ...",
              "snippet": "For the 2024 fiscal year, Embecta reported revenues of $1.123 billion, for a gain of 0.2%, including fourth-quarter sales of $286.1 million. Annual net income reached $78.3 million, compared to ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. regulatory compliance issues",
              "retrieved_at": "2025-01-06T17:47:07.392318+00:00",
              "published_date": null,
              "source_hash": "f07f08981f55ee2a3844c00b2ac4580c"
            },
            {
              "url": "",
              "title": "UPDATE - embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results",
              "snippet": "PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (\"embecta\") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Embecta Corp. Embecta Corp. pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:47:18.890189+00:00",
              "published_date": "2024-11-12T17:31:00+00:00",
              "source_hash": "db60f198606ba2ebedbefec10f1bd588"
            },
            {
              "url": "",
              "title": "Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps",
              "snippet": "Discover Fast-Growing Stocks Every Month On Tuesday, Embecta Corp EMBC posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. regulatory compliance issues",
              "retrieved_at": "2025-01-06T17:47:09.915617+00:00",
              "published_date": "2024-11-26T13:15:00+00:00",
              "source_hash": "561dc7221431305e7ea8bbc73d71bdc0"
            },
            {
              "url": "",
              "title": "Embecta Corp. (NASDAQ:EMBC) Q4 2024 Earnings Call Transcript",
              "snippet": "Embecta Corp. (NASDAQ:EMBC) Q4 2024 Earnings Call Transcript ... and supply chain and labor issues. Despite these factors, which we estimate cost us roughly 500 basis points negative margin ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. regulatory compliance issues",
              "retrieved_at": "2025-01-06T17:47:09.915650+00:00",
              "published_date": "2024-11-27T13:13:00+00:00",
              "source_hash": "f61814c379173542a0bc5b57363002d1"
            },
            {
              "url": "",
              "title": "Embecta Corp. (NASDAQ:EMBC) Shares Sold by Thrivent Financial for Lutherans",
              "snippet": "Embecta Corp. has a fifty-two week low of $9.93 and a fifty-two week high of $21.48. Embecta ( NASDAQ:EMBC - Get Free Report ) last released its quarterly earnings results on Tuesday, November 26th.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. regulatory compliance issues",
              "retrieved_at": "2025-01-06T17:47:09.915677+00:00",
              "published_date": "2024-12-05T00:00:00+00:00",
              "source_hash": "8c5e0f70fe7bd1739f5bd3a85e8b6435"
            },
            {
              "url": "",
              "title": "Embecta (EMBC) Passes Through 3% Yield Mark",
              "snippet": "Looking at the universe of stocks we cover at Dividend Channel, in trading on Wednesday, shares of Embecta Corp (Symbol: EMBC) were yielding above the 3% mark based on its quarterly dividend ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Embecta Corp. Embecta Corp. pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:47:18.890374+00:00",
              "published_date": "2024-12-11T20:30:00+00:00",
              "source_hash": "3fcb9918e15eed0380e772137e9f61b4"
            },
            {
              "url": "",
              "title": "Embecta Corp. SEC 10-K Report \u2014 TradingView News",
              "snippet": "The company is also focused on improving productivity to offset increased costs due to inflation and supply chain disruptions. Strategic Initiatives. Embecta Corp. has undertaken several strategic initiatives, including the submission of a 510(k) premarket filing to the FDA for a proprietary disposable insulin delivery system, which received ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. supply chain disruptions",
              "retrieved_at": "2025-01-06T17:47:11.462250+00:00",
              "published_date": null,
              "source_hash": "7cc75e2845aa2c62dc32f78598b57149"
            },
            {
              "url": "",
              "title": "Envisioning a life unlimited by diabetes - embecta Corp.",
              "snippet": "macroeconomic challenges, including continuing COVID-19 lockdowns, supply chain disruptions, significant inflation and the war in Ukraine. Fiscal 2022 highlights ... Non-Executive Chairman, Embecta Corp. David J. Albritton 3,4 Founder and Chief Executive Officer, Nineteen88 Strategies",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. supply chain disruptions",
              "retrieved_at": "2025-01-06T17:47:11.462365+00:00",
              "published_date": null,
              "source_hash": "fd2b2507a986ee2fc09c650b26f8444a"
            },
            {
              "url": "",
              "title": "SEC Filing - embecta Corp.",
              "snippet": "On May 13, 2022, Embecta Corp. (the \"Company\" or \"embecta\") issued a press release (the \"Earnings Release\") regarding its results for the quarter ended March 31, 2022. The Earnings Release is included as Exhibit 99.1 to this report. ... transportation), and supply chain disruptions F/X \u2022 EUR/USD assumed to be ~1.07 \u2022 USD/YEN assumed ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. supply chain disruptions",
              "retrieved_at": "2025-01-06T17:47:11.462382+00:00",
              "published_date": null,
              "source_hash": "ad9d0014f958e34040a0923d4fcebf85"
            },
            {
              "url": "",
              "title": "Envisioning a life unlimited by diabetes - embecta Corp.",
              "snippet": "despite the ongoing macroeconomic challenges posed by inflation, supply chain disruptions, and geopolitical instability. This is thanks in large part to our unique position as an agile new company bolstered by a 100-year legacy ... Non-Executive Chairman, Embecta Corp. David J. Albritton 3,4 Founder and Chief Executive Officer, Nineteen88 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. supply chain disruptions",
              "retrieved_at": "2025-01-06T17:47:11.462396+00:00",
              "published_date": null,
              "source_hash": "30dd643ca4669c2cd04e305a1ef2bff2"
            },
            {
              "url": "",
              "title": "Embecta's Bold Move: Will This Insulin Needle Giant Be the Next Big ...",
              "snippet": "Embecta Corp.'s financial performance and operational efficiency are pivotal drivers that make it an attractive acquisition target. In the fiscal second quarter of 2024, Embecta reported a revenue of $287.2 million, marking an increase of 3.6% on an as-reported basis and 4.5% on a constant currency basis.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. supply chain disruptions",
              "retrieved_at": "2025-01-06T17:47:11.462409+00:00",
              "published_date": null,
              "source_hash": "3594ef1e0485c912a85ee5b874d0258a"
            },
            {
              "url": "",
              "title": "Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full - GlobeNewswire",
              "snippet": "embecta is a global diabetes care company that is leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. supply chain disruptions",
              "retrieved_at": "2025-01-06T17:47:11.462423+00:00",
              "published_date": null,
              "source_hash": "d8fbf8700410cd3119beb3106d9fea24"
            },
            {
              "url": "",
              "title": "EMBECTA CORP. Management's Discussion and Analysis of Financial ...",
              "snippet": "In particular, tariffs or other trade barriers imposed by the United States or other countries could adversely impact its supply chain costs or otherwise adversely impact its results of operations. \u2022Any impact of the COVID-19 pandemic on embecta's business, including disruptions in its operations and supply chains.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. supply chain disruptions",
              "retrieved_at": "2025-01-06T17:47:11.462436+00:00",
              "published_date": null,
              "source_hash": "75f69f07f6119f9a4e229990d4d8f3a5"
            },
            {
              "url": "",
              "title": "EMBECTA CORP. Management's Discussion and Analysis of Financial ...",
              "snippet": "Various governmental measures to slow and control the spread of COVID-19 have led to a shift in healthcare priorities, supply chain constraints and the disruption of economic activities worldwide. As further discussed below, our future 29 ----- operating performance may be subject to further volatility due to the significant uncertainty with ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. supply chain disruptions",
              "retrieved_at": "2025-01-06T17:47:11.462447+00:00",
              "published_date": null,
              "source_hash": "09825a871dc68555b08e6a23af86b2e5"
            },
            {
              "url": "",
              "title": "Challenges and Prospects for Embecta - Value the Markets",
              "snippet": "What You Need To Know. Embecta Corp (NASDAQ: EMBC), the world's largest producer of insulin pen needles and syringes, is considering a sale after underperforming post-separation from Becton Dickinson. The company has seen a 70% drop in its share price since becoming a standalone entity. Despite challenges from GLP-1 drugs impacting its US sales, Embecta's CEO believes in the lasting ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. supply chain disruptions",
              "retrieved_at": "2025-01-06T17:47:11.462458+00:00",
              "published_date": null,
              "source_hash": "4dee6333df32c74ed972329f88869b6d"
            },
            {
              "url": "",
              "title": "Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program ...",
              "snippet": "On Tuesday, Embecta Corp (NASDAQ:EMBC) posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago. The company reported ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. supply chain disruptions",
              "retrieved_at": "2025-01-06T17:47:11.462471+00:00",
              "published_date": null,
              "source_hash": "fd669e9a12f10d063e0e76bdd589f954"
            },
            {
              "url": "",
              "title": "Embecta Corp. (NASDAQ:EMBC) Q4 2024 Earnings Call Transcript",
              "snippet": "Embecta Corp. (NASDAQ:EMBC ... geopolitical conflicts, and supply chain and labor issues. Despite these factors, which we estimate cost us roughly 500 basis points negative margin impact, our ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. supply chain disruptions",
              "retrieved_at": "2025-01-06T17:47:14.888852+00:00",
              "published_date": "2024-11-27T13:13:00+00:00",
              "source_hash": "0f7a0a3a3100fec501ad1e71c42716cd"
            },
            {
              "url": "",
              "title": "embecta to Participate at the 43rd Annual J.P. Morgan Healthcare Conference",
              "snippet": "PARSIPPANY, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Embecta Corp. Embecta Corp. pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:47:18.890351+00:00",
              "published_date": "2024-12-19T00:00:00+00:00",
              "source_hash": "9ec1e757b10462e70bf4d35726b8aa8c"
            },
            {
              "url": "",
              "title": "Form DEF 14A - Other definitive proxy statements",
              "snippet": "I'm pleased to invite you to attend the 2024 Annual Meeting of Stockholders (2024 Annual Meeting) of Embecta Corp. (Embecta ... posed by inflation, supply chain disruptions, and geopolitical ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Embecta Corp. Embecta Corp. supply chain disruptions",
              "retrieved_at": "2025-01-06T17:47:14.888969+00:00",
              "published_date": "2023-12-31T22:31:00+00:00",
              "source_hash": "0e3cd9c04d074909fa31026fed03e335"
            },
            {
              "url": "",
              "title": "Embecta Corp. (EMBC) Stock Price, Quote & News - Stock Analysis",
              "snippet": "Get a real-time Embecta Corp. (EMBC) stock price quote with breaking news, financials, statistics, charts and more. Get a real-time Embecta Corp. (EMBC) stock price quote with breaking news, financials, statistics, charts and more. ... Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Embecta Corp. Embecta Corp. pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:47:16.436758+00:00",
              "published_date": null,
              "source_hash": "0a316499c013377591521d3b365a1b82"
            },
            {
              "url": "",
              "title": "What is the current Price Target and Forecast for Embecta Corp. (EMBC)",
              "snippet": "Based on short-term price targets offered by three analysts, the average price target for Embecta Corp. comes to $22.00. The forecasts range from a low of $20.00 to a high of $26.00.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Embecta Corp. Embecta Corp. pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:47:16.436776+00:00",
              "published_date": null,
              "source_hash": "b477d33c498a643a1f704912a62edd6a"
            },
            {
              "url": "",
              "title": "Historical Price Lookup - embecta Corp.",
              "snippet": "For a discussion of certain factors that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K and other filings with the SEC. embecta expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Embecta Corp. Embecta Corp. pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:47:16.436789+00:00",
              "published_date": null,
              "source_hash": "084607b919543edcc6b6fd0d94e489cf"
            },
            {
              "url": "",
              "title": "Embecta Corp. (EMBC) Stock Price, News, Quote & History - Yahoo Finance",
              "snippet": "Find the latest Embecta Corp. (EMBC) stock quote, history, news and other vital information to help you with your stock trading and investing.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Embecta Corp. Embecta Corp. pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:47:16.436801+00:00",
              "published_date": null,
              "source_hash": "b965bbe2f614317446da8fad67bdae53"
            },
            {
              "url": "",
              "title": "Embecta Corp. (EMBC) Stock, Price, News, Quotes, Forecast and ... - MSN",
              "snippet": "Embecta Corp. is a global medical device company. The Company is focused on providing solutions to people living with diabetes. The Company has a portfolio of products, including a range of pen ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Embecta Corp. Embecta Corp. pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:47:16.436812+00:00",
              "published_date": null,
              "source_hash": "8f76cc5201b5f2c7ea31f40b721d0230"
            },
            {
              "url": "",
              "title": "Recommendation to Sell: Anticipated Costs and Competition Challenge ...",
              "snippet": "Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Embecta Corp. Embecta Corp. pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:47:16.436822+00:00",
              "published_date": null,
              "source_hash": "cb258f30385c50c2fe3ee39883134cb1"
            },
            {
              "url": "",
              "title": "Embecta Company Profile 2024: Stock Performance & Earnings - PitchBook",
              "snippet": "Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. ... As of 12-Dec-2024 the stock price of Embecta is $19.68. What is the current market cap of Embecta? The current market ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Embecta Corp. Embecta Corp. pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:47:16.436834+00:00",
              "published_date": null,
              "source_hash": "af6a129dd1770392b454b15f03f10d80"
            },
            {
              "url": "",
              "title": "Embecta Corp.: Target Price Consensus and Analysts Recommendations ...",
              "snippet": "Morgan Stanley Adjusts Price Target on Embecta to $31 From $33, Maintains Equal-Weight Rating 22-12-21: MT Morgan Stanley Adjusts Price Target on Embecta Corp. to $33 From $36, Reiterates Equalweight Rating 22-10-11: MT",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Embecta Corp. Embecta Corp. pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:47:16.436845+00:00",
              "published_date": null,
              "source_hash": "e69a53eaa0a36356d21ce04108738d4a"
            },
            {
              "url": "",
              "title": "Embecta Corp. (EMBC) Stock Price, News & Historical Data",
              "snippet": "Get the latest Embecta Corp. (EMBC) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Embecta Corp. Embecta Corp. pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:47:16.436859+00:00",
              "published_date": null,
              "source_hash": "ed0851bbaa3d1acab50351a77cb49987"
            },
            {
              "url": "",
              "title": "Embecta Corp. (NASDAQ:EMBC) Q4 2024 Earnings Call Transcript",
              "snippet": "Embecta Corp. (NASDAQ:EMBC) Q4 2024 Earnings Call ... the impact of the aforementioned distributor order timing, favorable pricing, and growth in the sales of non-diabetes products that were ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Embecta Corp. Embecta Corp. pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:47:18.890293+00:00",
              "published_date": "2024-11-27T13:13:00+00:00",
              "source_hash": "c396299617a988145c131479e513d616"
            },
            {
              "url": "",
              "title": "Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps",
              "snippet": "Embecta expects between $35 million and $45 million in pre-tax charges in 2025 related to its restructuring plan. Discover Fast-Growing Stocks Every Month On Tuesday, Embecta Corp EMBC posted the ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Embecta Corp. Embecta Corp. pricing and reimbursement controversies",
              "retrieved_at": "2025-01-06T17:47:18.890325+00:00",
              "published_date": "2024-11-26T13:15:00+00:00",
              "source_hash": "dc12eb0c8ad06c1b8aa9baa669ba1977"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Embecta Corp. regulatory compliance issues",
              "rationale": "Investigate potential legal and regulatory challenges related to product approvals and compliance",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Embecta Corp. supply chain disruptions",
              "rationale": "Examine risks associated with supply chain vulnerabilities and their impact on operations",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Embecta Corp. pricing and reimbursement controversies",
              "rationale": "Explore ethical and social concerns related to pricing strategies and reimbursement challenges in different regions",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T10:47:37.674893",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}